AbClon 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
4 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HLX22 / Fosun Pharma, AbClon
HLX22-GC-301, NCT06532006: A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Recruiting
3
550
Japan, US, RoW
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Shanghai Henlius Biotech, Henlius USA
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
06/27
09/28
HLX22-GC-201, NCT04908813: Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Active, not recruiting
2
150
RoW
HLX22, Placebo, Trastuzumab, Oxaliplatin, Capecitabine
Shanghai Henlius Biotech
Gastric Cancer
12/24
12/25
NCT06832202: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Recruiting
2
50
RoW
HLX22, Trastuzumab Deruxtecan
Shanghai Henlius Biotech
HER2-low Hormone Receptor Positive Breast Cancer
06/27
12/29
nespecabtagene autoleucel (AT101) / AbClon
AbClon, NCT05338931: Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
1/2
82
RoW
AT101(Anti-CD19 Chimeric Antigen Receptor T cell), AT101
AbClon
B-cell Non Hodgkin Lymphoma
03/30
09/30
AM105 / AbClon
No trials found
CLDN18.2 CAR-T / AbClon
No trials found
MSLN CAR-T / AbClon
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
HLX22 / Fosun Pharma, AbClon
HLX22-GC-301, NCT06532006: A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer

Recruiting
3
550
Japan, US, RoW
HLX22, Pembrolizumab, Trastuzumab, Oxaliplatin, Capecitabine
Shanghai Henlius Biotech, Henlius USA
Gastroesophageal-junction Cancer, Monoclonal Antibody, Gastric Cancer, HER2-positive Gastric Cancer
06/27
09/28
HLX22-GC-201, NCT04908813: Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer

Active, not recruiting
2
150
RoW
HLX22, Placebo, Trastuzumab, Oxaliplatin, Capecitabine
Shanghai Henlius Biotech
Gastric Cancer
12/24
12/25
NCT06832202: A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients

Recruiting
2
50
RoW
HLX22, Trastuzumab Deruxtecan
Shanghai Henlius Biotech
HER2-low Hormone Receptor Positive Breast Cancer
06/27
12/29
nespecabtagene autoleucel (AT101) / AbClon
AbClon, NCT05338931: Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Recruiting
1/2
82
RoW
AT101(Anti-CD19 Chimeric Antigen Receptor T cell), AT101
AbClon
B-cell Non Hodgkin Lymphoma
03/30
09/30
AM105 / AbClon
No trials found
CLDN18.2 CAR-T / AbClon
No trials found
MSLN CAR-T / AbClon
No trials found

Download Options